GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
Sample GSM2892617 Query DataSets for GSM2892617
Status Public on Apr 17, 2018
Title A549res-ctrl_3
Sample type RNA
Source name NSCLC, cisplatin resistant, control
Organism Homo sapiens
Characteristics sensitivity: resistant
treatment conc: 0
Treatment protocol For all experiments, cells were allowed to attach overnight, experienced 4 h of serum starvation and were subsequently treated with cisplatin for 24 h in IMDM medium without any supplements. The parental cells were treated with 11 µM cisplatin. The resistant sub-line was exposed to 11 µM cisplatin and additionally treated with 34 µM cisplatin. The control cells were treated with the drug-free medium.
Growth protocol The human NSCLC cell line A549 was obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA). Its cisplatin-resistant sub-line A549rCDDP2000 derived from the Resistant Cancer Cell Line (RCCL) collection ( had been established by adapting the growth of A549 cells in the presence of increasing concentrations of cisplatin until a final concentration of 2000 ng/mL cisplatin. A549 cells were grown in IMDM medium (PAN-Biotech, Aidenbach, Germany) containing 4 mM L-glutamine supplemented with 10 % foetal calf serum, 100 I.E./mL penicillin and 0.1 mg/mL streptomycin. The medium of the A549rCDDP2000 cells additionally contained 2 µg/mL cisplatin. Cells were cultivated as monolayers in a humidified atmosphere at 37 °C and 5 % CO2.
Extracted molecule total RNA
Extraction protocol Total ribonucleic acid (RNA) was isolated from the cells with my-Budget RNA Mini Kit (Bio-Budget, Krefeld, Germany) through different spin columns according to the manufacturer’s instructions. Isolated RNA was stored at -80 °C until analysis was performed.
Label Cy3
Label protocol Transcriptome was then analysed using One-Color Whole Genome Array SurePrint G3 Human GE V2 8x60K Kit (Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer’s instructions. Briefly, total RNA was transcribed to complementary deoxyribonucleic acid (cDNA) using AffinityScript-RT, Oligo dT-Promoter Primer and T7 RNA Polymerase and labelled using the One Colour RNA Spike-In Kit (positive controls) including Cyanin 3-CTP (Cy3) dye.
Hybridization protocol After purifying the labelled/amplified complementary RNA (cRNA) using silica-membrane RNeasy spin columns from the RNeasy® Mini Kit (Qiagen, Venlo, the Netherlands), cRNA was quantified spectrophotometrically using NanoDropTM ND-1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA). 40 µL of equivalent amounts of Cy3-labelled cRNA in 10x Blocking Agent and 25x Fragmentation Buffer, diluted with 2x GEx HI-RPM Hybridization Buffer were loaded on the gaskets of the microarray slide and kept at 65 °C for 17 h with 10 rpm of agitation.
Scan protocol After washing twice with different washing buffers, the microarray was read out with the SureScan Microarray Scanner System (Agilent Technologies, Santa Clara, CA, USA) to obtain immunofluorescence intensity.
Description gene expression in untreated res. cells
Data processing Array data were pre-processed via background correction (exponential convolution method) and quantile normalization. Statistical significances of dose- and resistance-induced gene expression changes were analysed using limma, a linear model-based technique. Differential expression was declared at a 5 % false discovery rate (FDR) cut-off together with an at least twofold up- or downregulation. The overall significance of the signature of differentially expressed genes was assessed via a global test. VALUE contains quantile normalized data for probes with REFSEQ IDs only (29,729)
Submission date Dec 18, 2017
Last update date Apr 17, 2018
Contact name Ganna Kalayda
Organization name University of Bonn
Department Clinical Pharmacy
Street address An der Immenburg 4
City Bonn
ZIP/Postal code 53121
Country Germany
Platform ID GPL17077
Series (1)
GSE108214 Key players of cisplatin resistance: towards a systems pharmacology approach

Data table header descriptions
VALUE quantile

Data table
A_23_P117082 13.21658673
A_33_P3246448 5.228036464
A_33_P3318220 5.540846641
A_21_P0000509 17.50116694
A_21_P0000744 11.07880238
A_24_P215804 7.464647192
A_23_P110167 11.96406495
A_33_P3211513 7.570539801
A_23_P103349 5.190385134
A_32_P61480 5.522417501
A_33_P3788124 5.555297354
A_33_P3414202 6.569932009
A_33_P3316686 8.722049298
A_33_P3300975 6.129160402
A_33_P3263061 11.03983772
A_24_P278460 9.096824177
A_21_P0014651 7.957571723
A_23_P340890 10.28904884
A_21_P0010885 11.46495146
A_23_P89762 8.154678747

Total number of rows: 29729

Table truncated, full table size 728 Kbytes.

Supplementary file Size Download File type/resource
GSM2892617_SG11440003_253949429103_S001_GE1_1100_Jul11_1_3.txt.gz 3.1 Mb (ftp)(http) TXT
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap